{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:16:00Z","timestamp":1768972560790,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"LMU Munich Clinician Scientist Program","award":["MCSP Track Metiphys"],"award-info":[{"award-number":["MCSP Track Metiphys"]}]},{"name":"LMU Munich Clinician Scientist Program","award":["MCSP Track Metiphys"],"award-info":[{"award-number":["MCSP Track Metiphys"]}]},{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>In patients with unresectable stage III non-small-cell lung cancer (NSCLC), durvalumab maintenance treatment after chemoradiotherapy (CRT) significantly improves survival. So far, however, metabolic changes of tumoral lesions and secondary lymphoid organs under durvalumab are unknown. Hence, we assessed changes on [<jats:sup>18<\/jats:sup>F]FDG PET\/CT in comparison to patients undergoing CRT alone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Forty-three patients with [<jats:sup>18<\/jats:sup>F]FDG PET\/CT both before and after standard CRT for unresectable stage III NSCLC were included, in 16\/43 patients durvalumab maintenance treatment was initiated (CRT-IO) prior to the second PET\/CT. Uptake of tumor sites and secondary lymphoid organs was compared between CRT and CRT-IO. Also, readers were blinded for durvalumab administration and reviewed scans for findings suspicious for immunotherapy-related adverse events (irAE).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Initial uptake characteristics were comparable. However, under durvalumab, diverging metabolic patterns were noted: There was a significantly higher reduction of tumoral uptake intensity in CRT-IO compared to CRT, e.g. median decrease of SUV<jats:sub>max<\/jats:sub> \u201370.0% vs. \u201324.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.009. In contrast, the spleen uptake increased in CRT-IO while it dropped in CRT (median\u2009+\u200912.5% vs. \u20134.4%, <jats:italic>p<\/jats:italic>\u2009=\u20090.029). Overall survival was significantly longer in CRT-IO compared to CRT with few events (progression\/death) noted in CRT-IO. Findings suggestive of irAE were present on PET\/CT more often in CRT-IO (12\/16) compared to CRT (8\/27 patients), <jats:italic>p<\/jats:italic>\u2009=\u20090.005.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Durvalumab maintenance treatment after CRT leads to diverging tumoral metabolic changes, but also increases splenic metabolism and leads to a higher proportion of findings suggestive of irAE compared to patients without durvalumab. Due to significantly prolonged survival with durvalumab, survival analysis will be substantiated in correlation to metabolic changes as soon as more clinical events are present.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-023-06192-6","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T08:03:28Z","timestamp":1679558608000},"page":"2466-2476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Metabolic patterns on [18F]FDG PET\/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy\u2009\u00b1\u2009durvalumab maintenance treatment"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-8438","authenticated-orcid":false,"given":"Adrien","family":"Holzgreve","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Taugner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"K\u00e4smann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Tufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Reinmuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minglun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Winkelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena M.","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander E.","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bartenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chukwuka","family":"Eze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farkhad","family":"Manapov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"6192_CR1","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379:2342\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1809697.","journal-title":"N Engl J Med"},{"key":"6192_CR2","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377:1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"N Engl J Med"},{"key":"6192_CR3","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/jco.21.02528","volume":"40","author":"ME Daly","year":"2022","unstructured":"Daly ME, Singh N, Ismaila N, Antonoff MB, Arenberg DA, Bradley J, et al. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol. 2022;40:1356\u201384. https:\/\/doi.org\/10.1200\/jco.21.02528.","journal-title":"J Clin Oncol"},{"key":"6192_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41571-021-00501-4","volume":"18","author":"JE Chaft","year":"2021","unstructured":"Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG, Cascone T. Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol. 2021;18:547\u201357. https:\/\/doi.org\/10.1038\/s41571-021-00501-4.","journal-title":"Nat Rev Clin Oncol"},{"key":"6192_CR5","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jtho.2020.12.015","volume":"16","author":"C Faivre-Finn","year":"2021","unstructured":"Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thoracic Oncol. 2021;16:860\u20137. https:\/\/doi.org\/10.1016\/j.jtho.2020.12.015.","journal-title":"J Thoracic Oncol"},{"key":"6192_CR6","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.annonc.2020.03.287","volume":"31","author":"L Paz-Ares","year":"2020","unstructured":"Paz-Ares L, Spira A, Raben D, Planchard D, Cho BC, \u00d6zg\u00fcro\u011flu M, et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol. 2020;31:798\u2013806. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.287.","journal-title":"Ann Oncol"},{"key":"6192_CR7","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/jco.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40:1301\u201311. https:\/\/doi.org\/10.1200\/jco.21.01308.","journal-title":"J Clin Oncol"},{"key":"6192_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cpet.2014.07.006","volume":"9","author":"S Basu","year":"2014","unstructured":"Basu S, Hess S, Nielsen Braad PE, Olsen BB, Inglev S, H\u00f8ilund-Carlsen PF. The Basic Principles of FDG-PET\/CT Imaging. PET Clinics. 2014;9:355\u201370. https:\/\/doi.org\/10.1016\/j.cpet.2014.07.006.","journal-title":"PET Clinics"},{"key":"6192_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrclinonc.2015.75","volume":"12","author":"W Grootjans","year":"2015","unstructured":"Grootjans W, de Geus-Oei LF, Troost EG, Visser EP, Oyen WJ, Bussink J. PET in the management of locally advanced and metastatic NSCLC. Nat Rev Clin Oncol. 2015;12:395\u2013407. https:\/\/doi.org\/10.1038\/nrclinonc.2015.75.","journal-title":"Nat Rev Clin Oncol"},{"key":"6192_CR10","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1007\/s00259-021-05624-5","volume":"49","author":"SC Vaz","year":"2022","unstructured":"Vaz SC, Adam JA, Delgado Bolton RC, Vera P, van Elmpt W, Herrmann K, et al. Joint EANM\/SNMMI\/ESTRO practice recommendations for the use of 2-[(18)F]FDG PET\/CT external beam radiation treatment planning in lung cancer V1.0. Eur J Nucl Med Mol Imaging. 2022;49:1386\u2013406. https:\/\/doi.org\/10.1007\/s00259-021-05624-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6192_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1053\/j.semnuclmed.2022.05.003","volume":"52","author":"F Manapov","year":"2022","unstructured":"Manapov F, Eze C, Holzgreve A, K\u00e4smann L, Nieto A, Taugner J, et al. PET\/CT for Target Delineation of Lung Cancer Before Radiation Therapy. Semin Nucl Med. 2022;52:673\u201380. https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.05.003.","journal-title":"Semin Nucl Med"},{"key":"6192_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","volume":"46","author":"N Aide","year":"2019","unstructured":"Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET\/CT for assessing tumour response to immunotherapy\u202f: Report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2019;46:238\u201350. https:\/\/doi.org\/10.1007\/s00259-018-4171-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6192_CR13","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1007\/s00259-021-05211-8","volume":"48","author":"C Eze","year":"2021","unstructured":"Eze C, Schmidt-Hegemann NS, Sawicki LM, Kirchner J, Roengvoraphoj O, K\u00e4smann L, et al. PET\/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC-current state and future directions. Eur J Nucl Med Mol Imaging. 2021;48:3975\u201389. https:\/\/doi.org\/10.1007\/s00259-021-05211-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6192_CR14","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00259-021-05584-w","volume":"49","author":"M Unterrainer","year":"2022","unstructured":"Unterrainer M, Taugner J, K\u00e4smann L, Tufman A, Reinmuth N, Li M, et al. Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy \u00b1 immune checkpoint inhibition. Eur J Nucl Med Mol Imaging. 2022;49:1407\u201316. https:\/\/doi.org\/10.1007\/s00259-021-05584-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6192_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"6192_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/00004728-198306000-00007","volume":"7","author":"L Cools","year":"1983","unstructured":"Cools L, Osteaux M, Divano L, Jeanmart L. Prediction of splenic volume by a simple CT measurement: a statistical study. J Comput Assist Tomogr. 1983;7:426\u201330. https:\/\/doi.org\/10.1097\/00004728-198306000-00007.","journal-title":"J Comput Assist Tomogr"},{"key":"6192_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, England\u202f: 1990). 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"key":"6192_CR18","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1007\/s00432-017-2488-1","volume":"143","author":"J Goebel","year":"2017","unstructured":"Goebel J, Hoischen J, Gramsch C, Schemuth HP, Hoffmann AC, Umutlu L, et al. Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria. J Cancer Res Clin Oncol. 2017;143:2527\u201333. https:\/\/doi.org\/10.1007\/s00432-017-2488-1.","journal-title":"J Cancer Res Clin Oncol"},{"key":"6192_CR19","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s00259-017-3887-x","volume":"45","author":"AK Seitz","year":"2018","unstructured":"Seitz AK, Rauscher I, Haller B, Kr\u00f6nke M, Luther S, Heck MM, et al. Preliminary results on response assessment using (68)Ga-HBED-CC-PSMA PET\/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging. 2018;45:602\u201312. https:\/\/doi.org\/10.1007\/s00259-017-3887-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6192_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s41747-020-00190-1","volume":"4","author":"M Unterrainer","year":"2020","unstructured":"Unterrainer M, Ruzicka M, Fabritius MP, Mittlmeier LM, Winkelmann M, R\u00fcbenthaler J, et al. PET\/CT imaging for tumour response assessment to immunotherapy: current status and future directions. Eur Radiol Exp. 2020;4:63. https:\/\/doi.org\/10.1186\/s41747-020-00190-1.","journal-title":"Eur Radiol Exp"},{"key":"6192_CR21","doi-asserted-by":"publisher","unstructured":"IC Kok, JS Hooiveld, PP van de Donk, D Giesen, EL van der Veen, MN Lub-de Hooge, et al. (89)Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer. Ann Oncol. 2022;33:80-8. https:\/\/doi.org\/10.1016\/j.annonc.2021.10.213.","DOI":"10.1016\/j.annonc.2021.10.213"},{"key":"6192_CR22","doi-asserted-by":"publisher","first-page":"720","DOI":"10.2967\/jnumed.121.262485","volume":"63","author":"MD Farwell","year":"2022","unstructured":"Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, et al. CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of (89)Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody. J Nucl Med. 2022;63:720\u20136. https:\/\/doi.org\/10.2967\/jnumed.121.262485.","journal-title":"J Nucl Med"},{"key":"6192_CR23","doi-asserted-by":"publisher","first-page":"110200","DOI":"10.1016\/j.ejrad.2022.110200","volume":"149","author":"Y Yao","year":"2022","unstructured":"Yao Y, Zhou X, Zhang A, Ma X, Zhu H, Yang Z, et al. The role of PET molecular imaging in immune checkpoint inhibitor therapy in lung cancer: Precision medicine and visual monitoring. Eur J Radiol. 2022;149:110200. https:\/\/doi.org\/10.1016\/j.ejrad.2022.110200.","journal-title":"Eur J Radiol"},{"key":"6192_CR24","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1007\/s00259-019-04573-4","volume":"47","author":"O Humbert","year":"2020","unstructured":"Humbert O, Cadour N, Paquet M, Schiappa R, Poudenx M, Chardin D, et al. (18)FDG PET\/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. Eur J Nucl Med Mol Imaging. 2020;47:1158\u201367. https:\/\/doi.org\/10.1007\/s00259-019-04573-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6192_CR25","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1007\/s00259-020-04815-w","volume":"47","author":"A Iravani","year":"2020","unstructured":"Iravani A, Osman MM, Weppler AM, Wallace R, Galligan A, Lasocki A, et al. FDG PET\/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. Eur J Nucl Med Mol Imaging. 2020;47:2776\u201386. https:\/\/doi.org\/10.1007\/s00259-020-04815-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6192_CR26","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00259-019-04615-x","volume":"47","author":"RD Seban","year":"2020","unstructured":"Seban RD, Mezquita L, Berenbaum A, Dercle L, Botticella A, Le Pechoux C, et al. Baseline metabolic tumor burden on FDG PET\/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging. 2020;47:1147\u201357. https:\/\/doi.org\/10.1007\/s00259-019-04615-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6192_CR27","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1007\/s00259-020-05103-3","volume":"48","author":"K Prigent","year":"2021","unstructured":"Prigent K, Lasnon C, Ezine E, Janson M, Coudrais N, Joly E, et al. Assessing immune organs on (18)F-FDG PET\/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients. Eur J Nucl Med Mol Imaging. 2021;48:2573\u201385. https:\/\/doi.org\/10.1007\/s00259-020-05103-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6192_CR28","doi-asserted-by":"publisher","first-page":"925","DOI":"10.7150\/thno.35989","volume":"10","author":"J Schwenck","year":"2020","unstructured":"Schwenck J, Sch\u00f6rg B, Fiz F, Sonanini D, Forschner A, Eigentler T, et al. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo(18)F-FDG-PET. Theranostics. 2020;10:925\u201337. https:\/\/doi.org\/10.7150\/thno.35989.","journal-title":"Theranostics"},{"key":"6192_CR29","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00259-020-05126-w","volume":"48","author":"RD Seban","year":"2021","unstructured":"Seban RD, Champion L, Schwartz LH, Dercle L. Spleen glucose metabolism on [(18)F]-FDG PET\/CT: a dynamic double-edged biomarker predicting outcome in cancer patients. Eur J Nucl Med Mol Imaging. 2021;48:2309\u201311. https:\/\/doi.org\/10.1007\/s00259-020-05126-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6192_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321\u201330. https:\/\/doi.org\/10.1038\/nature21349.","journal-title":"Nature"},{"key":"6192_CR31","doi-asserted-by":"publisher","first-page":"731798","DOI":"10.3389\/fphar.2021.731798","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z. PD-1\/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Front Pharmacol. 2021;12:731798. https:\/\/doi.org\/10.3389\/fphar.2021.731798.","journal-title":"Front Pharmacol"},{"key":"6192_CR32","doi-asserted-by":"publisher","unstructured":"F Seith, A Forschner, B Weide, B G\u00fcckel, M Schwartz, J Schwenck, et al. Is there a link between very early changes of primary and secondary lymphoid organs in (18)F-FDG-PET\/MRI and treatment response to checkpoint inhibitor therapy? J Immunother Cancer. 2020;8. https:\/\/doi.org\/10.1136\/jitc-2020-000656.","DOI":"10.1136\/jitc-2020-000656"},{"key":"6192_CR33","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.lungcan.2022.06.005","volume":"174","author":"Y Kuang","year":"2022","unstructured":"Kuang Y, Pierce CM, Chang HC, Sosinsky AZ, Deitz AC, Keller SM, et al. Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A systematic literature review and meta-analysis. Lung Cancer (Amsterdam, Netherlands). 2022;174:174\u201385. https:\/\/doi.org\/10.1016\/j.lungcan.2022.06.005.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"6192_CR34","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1016\/j.cllc.2020.02.025","volume":"21","author":"J Naidoo","year":"2020","unstructured":"Naidoo J, Nishino M, Patel SP, Shankar B, Rekhtman N, Illei P, et al. Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020;21:e435\u201344. https:\/\/doi.org\/10.1016\/j.cllc.2020.02.025.","journal-title":"Clin Lung Cancer"},{"key":"6192_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00259-007-0563-6","volume":"35","author":"E Gontier","year":"2008","unstructured":"Gontier E, Fourme E, Wartski M, Blondet C, Bonardel G, Le Stanc E, et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008;35:95\u20139. https:\/\/doi.org\/10.1007\/s00259-007-0563-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6192_CR36","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16:563\u201380. https:\/\/doi.org\/10.1038\/s41571-019-0218-0.","journal-title":"Nat Rev Clin Oncol"},{"key":"6192_CR37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378:158\u201368. https:\/\/doi.org\/10.1056\/NEJMra1703481.","journal-title":"N Engl J Med"},{"key":"6192_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2217\/imt-2018-0201","volume":"11","author":"K Saleh","year":"2019","unstructured":"Saleh K, Khalife-Saleh N, Kourie HR. Do immune-related adverse events correlate with response to immune checkpoint inhibitors? Immunotherapy. 2019;11:257\u20139. https:\/\/doi.org\/10.2217\/imt-2018-0201.","journal-title":"Immunotherapy"},{"key":"6192_CR39","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1200\/jco.2012.47.5947","volume":"31","author":"M Machtay","year":"2013","unstructured":"Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, et al. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668\/RTOG 0235 trial. J Clin Oncol. 2013;31:3823\u201330. https:\/\/doi.org\/10.1200\/jco.2012.47.5947.","journal-title":"J Clin Oncol"},{"key":"6192_CR40","doi-asserted-by":"publisher","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","volume":"12","author":"JL Vos","year":"2021","unstructured":"Vos JL, Elbers JBW, Krijgsman O, Traets JJH, Qiao X, van der Leun AM, et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat Commun. 2021;12:7348. https:\/\/doi.org\/10.1038\/s41467-021-26472-9.","journal-title":"Nat Commun"},{"key":"6192_CR41","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.21037\/tlcr-21-1010","volume":"11","author":"L K\u00e4smann","year":"2022","unstructured":"K\u00e4smann L, Taugner J, Eze C, Nieto A, Pelikan C, Fl\u00f6rsch B, et al. Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study. Transl Lung Cancer Res. 2022;11:1503\u20139. https:\/\/doi.org\/10.21037\/tlcr-21-1010.","journal-title":"Transl Lung Cancer Res"},{"key":"6192_CR42","doi-asserted-by":"publisher","first-page":"e056708","DOI":"10.1136\/bmjopen-2021-056708","volume":"12","author":"F Hegi-Johnson","year":"2022","unstructured":"Hegi-Johnson F, Rudd SE, Wichmann C, Akhurst T, Roselt P, Trinh J, et al. ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0\/1 study characterising PD-L1 with (89)Zr-durvalumab (MEDI4736) PET\/CT in stage III NSCLC patients receiving chemoradiation study protocol. BMJ Open. 2022;12:e056708. https:\/\/doi.org\/10.1136\/bmjopen-2021-056708.","journal-title":"BMJ Open."},{"key":"6192_CR43","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2967\/jnumed.121.262473","volume":"63","author":"J Smit","year":"2022","unstructured":"Smit J, Borm FJ, Niemeijer AN, Huisman MC, Hoekstra OS, Boellaard R, et al. PD-L1 PET\/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer. J Nucl Med. 2022;63:686\u201393. https:\/\/doi.org\/10.2967\/jnumed.121.262473.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06192-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06192-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06192-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T05:04:40Z","timestamp":1686200680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06192-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["6192"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06192-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"assertion":[{"value":"3 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board of the Ludwig-Maximilians-Universit\u00e4t (LMU) approved the retrospective data analysis (#17\u2013230). The study was conducted in compliance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (GCP) and the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients included in the study gave written consent for the PET\/CT scans as part of the clinical routine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Farkhad Manapov receives an unrestricted Research Institutional Grant from AstraZeneca. Farkhad Manapov receives honoraria from AstraZeneca, Novartis, Roche, Lilly, Elekta and Brainlab. Farkhad Manapov serves in the advisory board of AstraZeneca, Novartis. The remaining authors did not declare conflicts of interest related to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}